Vanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference [Accessibility Statement] Skip NavigationWASHINGTON, Feb. 26, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the 2026 Citizens Life Sciences Conference in Miami on Wednesday, March 11, 2026. A corporate presentation is scheduled for 2:15 p.m. Eastern Time.The corporate presentation given at the Citizens Life Sciences Conference may be access ...

B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been updated, reflecting expected growth in the psychiatry franchise with peak BYSANTI sales now included and probability adjustments removed, the analyst tells investors in a research note. Base assumptions include mid-to-high single-digit quarter over quarter growth in BYSANTI/FANAPT prescriptions through 2026, t ...

Fanapt revenue growth of 24% was primarily driven by a 149% surge in new-to-brand prescriptions following the bipolar disorder commercial launch. Management attributes accelerating Fanapt momentum to targeted commercial investments, including direct-to-consumer campaigns and a sales force expansion to approximately 300 representatives. HETLIOZ revenue declined 7% due to generic competition, though the product has retained the majority of market share after three years of generic entry. The approval ...

For Hetlioz, full-year net product sales fell 7% to $71.4 million. Moran said the decline reflected lower volume and price net of deductions amid continued U.S. generic competition, while noting the brand “continued to retain the majority of market share despite generic competition now for over three years.” Ponvory net product sales were $27.4 million, down 2% versus 2024, with the company also noting that certain variable consideration tied to Ponvory sales remains subject to dispute.Total 2025 revenues a ...

分组1 - Gilead Sciences reported quarterly earnings of $1.86 per share, exceeding the Zacks Consensus Estimate of $1.83 per share, but down from $1.90 per share a year ago, representing an earnings surprise of +1.91% [1] - The company achieved revenues of $7.93 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.63% and up from $7.57 billion year-over-year [2] - Gilead shares have increased approximately 23.6% since the beginning of the year, significantly outperforming the S&P 500's gain of 1.7% [3] 分组2 - The earnings outlook for Gilead is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $1.90 on revenues of $6.84 billion, and for the current fiscal year, it is $8.61 on revenues of $30.04 billion [7] - The Medical - Biomedical and Genetics industry, to which Gilead belongs, is currently ranked in the top 36% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Intellia Therapeutics, Inc. (NTLA) shares experienced a 6.3% increase, closing at $14.83, driven by notable trading volume and a 52.6% gain over the past four weeks [1][2]. Group 1: Company Developments - The recent price surge is attributed to increased investor confidence following the FDA's lifting of the clinical hold on the MAGNITUDE-2 study for nexiguran ziclumeran (nex-z) in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) [2]. - Intellia has aligned with the FDA on study modifications and risk-mitigation measures, including enhanced liver safety monitoring, and plans to resume patient enrollment and dosing promptly [2]. Group 2: Financial Expectations - The company is expected to report a quarterly loss of $0.99 per share, reflecting a year-over-year change of +20.2%, with revenues projected at $11.85 million, down 7.9% from the previous year [3]. - The consensus EPS estimate for the quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4]. Group 3: Industry Context - Intellia Therapeutics holds a Zacks Rank of 3 (Hold) within the Zacks Medical - Biomedical and Genetics industry, while Vanda Pharmaceuticals (VNDA), another stock in the same industry, finished 3.1% higher at $8.02 and has returned 8.1% over the past month [5]. - Vanda's consensus EPS estimate has changed +7.7% over the past month to -$2.18, representing a significant year-over-year change of -2625%, and it currently holds a Zacks Rank of 2 (Buy) [6].

Company Overview - AnaptysBio, Inc. is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases [3] - The company's pipeline includes rosnilimab, a pathogenic T cell depleter, which has completed a Phase 2b trial for rheumatoid arthritis; ANB033, a CD122 antagonist, currently in a Phase 1b trial for celiac disease; and ANB101, a BDCA2 modulator, in a Phase 1a trial [3] - Anaptys has discovered and out-licensed multiple therapeutic antibodies, including a PD-1 antagonist (Jemperli) to GSK and an IL-36R antagonist (imsidolimab) to Vanda Pharmaceuticals [3] Upcoming Events - Daniel Faga, president and CEO of Anaptys, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 4:30 PM PT / 7:30 PM ET [1] - A live webcast of the presentation will be available on the investor section of the Anaptys website, with a replay accessible for at least 30 days following the event [2] Strategic Developments - Anaptys recently announced plans to separate its biopharma operations from its substantial royalty assets by year-end 2026, allowing investors to align their investment philosophies and portfolio allocation with the strategic opportunities and financial objectives of each company [4]

FDA Approvals & Rejections - ARS Pharma's neffy, a needle-free epinephrine nasal spray for emergency treatment of Type I allergic reactions, received approval in China, with commercial availability expected in spring 2026. The product generated $31.3 million in U.S. revenue in Q3 2025 [3][4]. - Vanda Pharmaceuticals' NEREUS, an oral NK-1 receptor antagonist for preventing motion-induced vomiting, received FDA approval, marking the first new treatment for motion sickness in over 40 years. The drug demonstrated a meaningful reduction in vomiting in clinical trials [5][6]. Clinical Trials - Breakthroughs & Setbacks - InflaRx's analyses from a halted Phase 3 trial of Vilobelimab in pyoderma gangrenosum indicated potential efficacy signals with longer treatment duration, prompting plans to discuss alternative endpoints with the FDA [15][17]. - SELLAS reported that survival in its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukaemia is extending longer than anticipated, potentially increasing the likelihood of a positive outcome [18][19]. - Ultragenyx announced that its Phase 3 studies for Setrusumab in Osteogenesis Imperfecta failed to meet primary endpoints, leading to a decline in investor confidence [20][21]. - Genmab decided to discontinue clinical development of Acasunlimab to focus on higher-priority programs, with no impact expected on its full-year 2025 financial guidance [22][23]. Corporate Actions - FONAR Corporation agreed to be taken private by a CEO-led acquisition group for $19.00 per share, valuing the transaction at a significant premium. The deal is expected to close in Q3 2026, subject to shareholder approval [12][13][14].

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks experiencing the largest losses [3]

Market Sentiment - The CNN Money Fear and Greed index showed a decline in overall market sentiment, remaining in the "Neutral" zone with a current reading of 45.8, down from 48.4 [1][4] - U.S. stocks settled lower, with the Dow Jones index falling more than 300 points, closing at 48,063.29, while the S&P 500 and Nasdaq Composite also recorded declines [1][3] Stock Performance - The S&P 500 increased by 16.39% for the year, marking its third consecutive double-digit annual surge, while the Nasdaq Composite gained 20.36% and the Dow added 12.97% in 2025 [2] - Vanda Pharmaceuticals Inc. saw its shares jump over 25% after receiving FDA approval for NEREUS, aimed at preventing motion-induced vomiting [2] - FuelCell Energy Inc. experienced an 8% decline in its shares following the filing for an amended common stock offering [2] Economic Data - U.S. initial jobless claims decreased by 16,000 to 199,000 for the week ending December 27, which was better than market estimates of 220,000 [3] - All sectors on the S&P 500 closed negatively, with real estate, industrials, and materials stocks recording the largest losses [3]